Chart Events
Performance Outlook
| Previous Close | 11.56 |
| Open | 11.86 |
| Bid | 4.70 x 800 |
| Ask | 11.82 x 1100 |
| Day's Range | 11.55 - 11.86 |
| 52 Week Range | 9.07 - 17.05 |
| Volume | |
| Avg. Volume | 4,730 |
| Market Cap | 814.878M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | 64.33 |
| EPS (TTM) | 0.18 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.64 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Related Research
- Valneva SEDaily – Vickers Top Buyers & Sellers for 06/29/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
Insider MonkeyValneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript September 21, 2023 Valneva SE misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.36. Operator: Good day, and thank you for standing by. Welcome to the Valneva Half Year 2023 Financial Results Call and Webcast. [Operator Instructions] Please note that today’s conference is being […]
GlobeNewswireValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive
- GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen
